Pichat P, Angel I, Arbilla S
Synthélabo Recherche, Rueil-Malmaison France.
Arzneimittelforschung. 1998 Feb;48(2):173-8.
The anti-inflammatory effect of mizolastine (CAS 108612-45-9, SL85.0324-00), a new non-sedative histamine H1-receptor antagonist, was assessed in comparison to loratadine, terfenadine and pyrilamine. Intraplantar injection of arachidonic acid (AA) into the rat paw was followed by a rapid and sustained (> or = 4h) inflammatory oedema. Mizolastine (0.1 to 10 mg/ kg p.o.) inhibited in a dose-dependent manner the time course of the AA-induced paw inflammation as from the dose of 0.1 mg/kg p.o. This effect was maintained for at least the 4 h of observation (-44% at 0.3 mg/kg p.o.) suggesting a long lasting action of mizolastine. Although with higher maximal effect, a similar time course of response was observed with dexamethasone at 0.1 mg/kg p.o. In contrast, at anti-histamine, doses, the histamine H1-receptor antagonists terfenadine (1 to 30 mg/kg p.o.), loratadine (10 mg/kg p.o.), and pyrilamine (10 mg/kg p.o.) failed to inhibit significantly the inflammatory action of AA. Moreover, under conditions of H1-receptors blockade (e.g. when co-administered with pyrilamine or loratadine (10 mg/kg p.o.), the inhibition by mizolastine (0.3 mg/kg) of AA-induced inflammation was unchanged. This suggests that the anti-inflammatory effect of mizolastine was unrelated to its histamine H1-receptor antagonist properties. It is proposed that a primary effect on the lipoxygenase pathway may contribute to this action of mizolastine. This is based on the observations that mizolastine inhibits 5-lipoxygenase activity in vitro. Furthermore, a high dose of mizolastine (50 mg/kg) did not affect the inflammatory response to carrageenin which is mediated by the cyclooxygenase pathway. Together, these data indicate that mizolastine is orally effective in this animal model for cutaneous inflammation. Combined with its blockade of histamine H1-receptors, this property may contribute to its possible use in allergic inflammation or other inflammatory states.
将新型非镇静性组胺H1受体拮抗剂咪唑斯汀(CAS 108612 - 45 - 9,SL85.0324 - 00)的抗炎作用与氯雷他定、特非那定和吡拉明进行了比较评估。向大鼠爪内注射花生四烯酸(AA)后,会迅速出现持续(≥4小时)的炎性水肿。咪唑斯汀(0.1至10毫克/千克,口服)从0.1毫克/千克口服剂量起,就以剂量依赖性方式抑制AA诱导的爪部炎症的时间进程。这种作用在至少4小时的观察期内持续存在(0.3毫克/千克口服时为-44%),表明咪唑斯汀具有持久作用。虽然地塞米松口服0.1毫克/千克时具有更高的最大效应,但观察到类似的反应时间进程。相比之下,在抗组胺剂量下,组胺H1受体拮抗剂特非那定(1至30毫克/千克,口服)、氯雷他定(10毫克/千克,口服)和吡拉明(10毫克/千克,口服)未能显著抑制AA的炎性作用。此外,在H1受体阻断的条件下(例如与吡拉明或氯雷他定(10毫克/千克,口服)共同给药时),咪唑斯汀(0.3毫克/千克)对AA诱导炎症的抑制作用不变。这表明咪唑斯汀的抗炎作用与其组胺H1受体拮抗剂特性无关。有人提出,对脂氧合酶途径的主要作用可能有助于咪唑斯汀的这种作用。这是基于以下观察结果:咪唑斯汀在体外抑制5 - 脂氧合酶活性。此外,高剂量的咪唑斯汀(50毫克/千克)不影响由环氧化酶途径介导的对角叉菜胶的炎性反应。总之,这些数据表明咪唑斯汀在该动物皮肤炎症模型中口服有效。结合其对组胺H1受体的阻断作用,这一特性可能有助于其在过敏性炎症或其他炎症状态中的可能应用。